News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CRBU, new 52 week low
CRBU, new 52 week low
what a piece of shit stock this you need to be very selective People got duped when
Pfizer bought some shares here at
On June 30, 2023, Pfizer invested $25 million in Caribou Biosciences, purchasing 4.69 million shares at $5.33 per share, boosting the gene-editing company's funding for its cell therapy programs.
https://www.cariboubio.com/pipeline/
Founder of CRSP on board here a lot of companies that fail in this space!
Jennifer Doudna, PhD
Jennifer is a co-founder of Caribou Biosciences. She is a professor of molecular and cell biology and chemistry at the University of California, Berkeley where she is the Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences; the president of the Innovative Genomics Institute; and investigator at the Howard Hughes Medical Institute; a senior investigator at the Gladstone Institutes; a faculty scientist in the physical biosciences division of Lawrence Berkeley National Laboratory; and a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Her research seeks to understand how non-coding RNA molecules control the expression of genetic information and she has published extensively in the field of CRISPR-Cas biology. Jennifer’s work and that of her collaborator Dr. Emmanuelle Charpentier was recognized by the award of the Nobel Prize in Chemistry 2020 as well as a 2015 Breakthrough Prize. Her work on CRISPR-Cas systems has also been recognized with the Paul Janssen Award for Biomedical Research, a Lurie Prize in Biomedical Sciences, and the Princess of Asturias award. Jennifer was also named to the 2015 TIME Magazine’s TIME 100 list of the 100 most influential people in the world. After serving as a member of the Yale University faculty for eight years, during which time she was promoted to Henry Ford II Professor of Molecular Biophysics and Biochemistry, she joined the University of California, Berkeley faculty in 2002. Jennifer earned a PhD in biochemistry from Harvard University and was a postdoctoral scholar at the University of Colorado Boulder.
$CRBU
CRBU. Under $2
CRBU under $2
CRBU under $3
CRBU under $2
CRBU under $3
CRBU under $3
CRBU under $3
CRBU new 52 week low
CRBU new 52 week low
CRBU new 52 week low
It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
CRBU new 52 week low
CRBU new 52 week low
CRBU under $5
CRBU new 52 week low
Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
|
Followers
|
5
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
41
|
|
Created
|
06/18/23
|
Type
|
Free
|
| Moderators | |||
AI
